A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Clinical trial NCT03459534 · RECRUITING

Trial details

NCT number: NCT03459534
Sponsor: Il-Yang Pharm. Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Myeloid Leukemia, Chronic Phase CML, Chronic Phase CML, Refractory CML - Philadelphia Chromosome

Start date: 2018-06-25
Primary completion: 2026-06-30
Enrollment: 173

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.